Relationship of body mass index with aromatisation and plasma and tissue oestrogen levels in postmenopausal breast cancer patients treated with aromatase inhibitors

European Journal of Cancer

Volumn 50, Issue 6, 2014, Pages 1055-1064

  Lønning, Per Eystein ^a,b   Haynes, Benjamin P ^c   Dowsett, Mitch ^c,d  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Aromatase; BMI; Breast cancer; Endocrine therapy; Estradiol; Obesity; Overweight

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; ANDROGEN; AROMATASE; AROMATASE INHIBITOR; ESTRANE DERIVATIVE; ESTROGEN; ESTRONE; ESTRONE SULFATE; EXEMESTANE; FORMESTANE; LETROZOLE; PYRIDOGLUTETHIMIDE;

ANDROGEN BLOOD LEVEL; ARTICLE; BODY MASS; BREAST CANCER; ENZYME INHIBITION; ESTRADIOL BLOOD LEVEL; ESTROGEN BLOOD LEVEL; ESTRONE BLOOD LEVEL; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; TISSUE LEVEL;

AROMATASE; BMI; BREAST CANCER; ENDOCRINE THERAPY; ESTRADIOL; OBESITY; OVERWEIGHT;

AGED; ANDROGENS; AROMATASE; AROMATASE INHIBITORS; BODY MASS INDEX; BREAST NEOPLASMS; ESTRADIOL; ESTROGENS; ESTRONE; FEMALE; HUMANS; MIDDLE AGED; NITRILES; OUTCOME ASSESSMENT (HEALTH CARE); POSTMENOPAUSE; TRIAZOLES;

EID: 84897048053     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2014.01.007     Document Type: Article

References (40)

1. T.J. Key, P.N. Appleby, G.K. Reeves, A. Roddam, J.F. Dorgan, and C. Longcope et al. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women J Natl Cancer Inst 95 2003 1218 1226
2. M.L. Kwan, W.Y. Chen, C.H. Kroenke, E.K. Weltzien, J.M. Beasley, and S.J. Nechuta et al. Pre-diagnosis body mass index and survival after breast cancer in the After Breast Cancer Pooling Project Breast Cancer Res Treat 132 2012 729 739
3. J. Poortman Thijssen JHH, Waard Fd. Plasma oestrone, oestradiol and androstenedione levels in post-menopausal women: Relation to body weight and height Maturitas 3 1981 65 71
4. D.R. Meldrum, B.J. Davidson, I.V. Tataryn, and H.L. Judd Changes in circulating steroids with aging in postmenopausal women Obstet Gynecol 57 1981 624 627
5. M. Dowsett, J. Cuzick, J. Ingle, A. Coates, J. Forbes, and J. Bliss et al. Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen J Clin Oncol 28 2010 509 518
6. G. Pfeiler, R. Konigsberg, C. Fesl, B. Mlineritsch, H. Stoeger, and C.F. Singer et al. Impact of Body Mass Index on the Efficacy of Endocrine Therapy in Premenopausal Patients With Breast Cancer: An Analysis of the Prospective ABCSG-12 Trial J Clin Oncol 29 2011 2653 2659
7. I. Sestak, W. Distler, J.F. Forbes, M. Dowsett, A. Howell, and J. Cuzick Effect of Body Mass Index on Recurrences in Tamoxifen and Anastrozole Treated Women: An Exploratory Analysis From the ATAC Trial J Clin Oncol 28 2010 3411 3415
8. M. Ewertz, K.P. Gray, M.M. Regan, B. Ejlertsen, K.N. Price, and B. Thurlimann et al. Obesity and Risk of Recurrence or Death After Adjuvant Endocrine Therapy With Letrozole or Tamoxifen in the Breast International Group 1-98 Trial J Clin Oncol 30 2012 3967 3975
9. P.E. Lønning Aromatase inhibitors in breast cancer End-Rel-Cancer 11 2004 179 189
10. J. Geisler, N. King, M. Dowsett, L. Ottestad, S. Lundgren, and P. Walton et al. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer Br J Cancer 74 1996 1286 1291
11. J. Geisler, N. King, G. Anker, G. Ornati, E. Di Salle, and P.E. Lønning et al. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients Clin Cancer Res 4 1998 2089 2093
12. J. Geisler, B. Haynes, G. Anker, M. Dowsett, and P.E. Lønning Influence of letrozole (Femara) and anastrozole (Arimidex) on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over-designed study J Clin Oncol 20 2002 751 757
13. I.E. Smith, and M. Dowsett Drug therapy: Aromatase inhibitors in breast cancer N Engl J Med 348 2003 2431 2442
14. P.E. Lønning, M. Dowsett, and T.J. Powles Postmenopausal estrogen synthesis and metabolism: Alterations caused by aromatase inhibitors used for the treatment of breast cancer J Steroid Biochem 35 1990 355 366
15. A.L. Jones, F. MacNeill, S. Jacobs, P.E. Lønning, M. Dowsett, and T.J. Powles The influence of intramuscular 4-hydroxyandrostenedione on peripheral aromatisation in breast cancer patients Eur J Cancer 28A 1992 1712 1716
16. F.A. MacNeill, S. Jacobs, M. Dowsett, P.E. Lønning, and T.J. Powles The effects of oral 4-hydroxyandrostenedione on peripheral aromatisation in post-menopausal breast cancer patients Cancer Chemother Pharmacol 36 1995 249 254
17. F.A. MacNeill, S. Jacobs, P.E. Lønning, T.J. Powles, and M. Dowsett Combined treatment with 4-hydroxyandrostenedione and aminoglutethimide: Effects on aromatase inhibition and oestrogen suppression Br J Cancer 69 1994 1171 1175
18. F.A. MacNeill, A.L. Jones, S. Jacobs, P.E. Lønning, T.J. Powles, and M. Dowsett The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer Br J Cancer 66 1992 692 697
19. J. Geisler, D. Ekse, H. Helle, N. Duong, and P. Lønning An optimised, highly sensitive radioimmunoassay for the simultaneous measurement of estrone, estradiol and estrone sulfate in the ultra-low range in human plasma samples J Steroid Biochem Molec Biol 109 2008 90 95
20. J. Geisler, H. Helle, D. Ekse, N.K. Duong, D.B. Evans, and Y. Nordbo et al. Letrozole is Superior to Anastrozole in Suppressing Breast Cancer Tissue and Plasma Estrogen Levels Clin Cancer Res 14 2008 6330 6335
21. P.E. Lønning, and D. Ekse A sensitive assay for measurement of plasma estrone sulphate in patients on treatment with aromatase inhibitors J Steroid Biochem Mol Biol 55 1995 409 412
22. S.I. Helle, D. Ekse, J.M. Holly, and P.E. Lønning The IGF-system in healthy pre- and postmenopausal women: relations to demographic variables and sex-steroids J Steroid Biochem Mol Biol 81 2002 95 102
23. P.E. Lønning, S.I. Helle, D.C. Johannessen, H. Adlercreutz, E.A. Lien, and M. Tally et al. Relations between sex hormones, sex hormone binding globulin, insulin-like growth factor-I and insulin-like growth factor binding protein-1 in post-menopausal breast cancer patients Clin Endocrinol 42 1995 23 30
24. S. Jacobs, F. MacNeill, P. Lønning, M. Dowsett, A. Jones, and T. Powles Aromatase activity, serum oestradiol and their correlation with demographic indices J Steroid Biochem Mol Biol 41 1992 3 8
25. P.E. Lønning, H. Helle, N.K. Duong, D. Ekse, T. Aas, and J. Geisler Tissue estradiol is selectively elevated in receptor positive breast cancers while tumour estrone is reduced independent of receptor status J Steroid Biochem Mol Biol 117 2009 31 41
26. E.J. Folkerd, J.M. Dixon, L. Renshaw, R.P. A'Hern, and M. Dowsett Suppression of Plasma Estrogen Levels by Letrozole and Anastrozole Is Related to Body Mass Index in Patients With Breast Cancer J Clin Oncol 30 2012 2977 2980
27. D.C. Johannessen, T. Engan, Ed. Salle, M.G. Zurlo, J. Paolini, and G. Ornati et al. Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study Clin Cancer Res 3 1997 1101 1108
28. C. Diorio, J. Lemieux, L. Provencher, J.C. Hogue, and E. Vachon Aromatase inhibitors in obese breast cancer patients are not associated with increased plasma estradiol levels Breast Cancer Res Treatm 136 2012 573 579
29. S.E. Bulun, D. Chen, I. Moy, D.C. Brooks, and H. Zhao Aromatase, breast cancer and obesity: a complex interaction Trends Endocrinol Metab 23 2012 83 89
30. B.P. Haynes, A.H. Straume, J. Geisler, R. A'Hern, H. Helle, and I.E. Smith et al. Intratumoral Estrogen Disposition in Breast Cancer Clin Cancer Res 16 2010 1790 1801
31. A.K. Dunbier, H. Anderson, Z. Ghazoui, E.J. Folkerd, R. A'Hern, and R.J. Crowder et al. Relationship Between Plasma Estradiol Levels and Estrogen-Responsive Gene Expression in Estrogen Receptor-Positive Breast Cancer in Postmenopausal Women J Clin Oncol 28 2010 1161 1167
32. P.E. Lønning, B.P. Haynes, A.H. Straume, A. Dunbier, H. Helle, and S. Knappskog et al. Exploring breast cancer estrogen disposition: the basis for endocrine manipulation Clin Cancer Res 17 2011 4948 4958
33. A.J. Lee, M.X. Cai, P.E. Thomas, A.H. Conney, and B.T. Zhu Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms Endocrinology 144 2003 3382 3398
34. P.E. Lønning, S. Kvinnsland, T. Thorsen, and P.M. Ueland Alterations in the metabolism of oestrogens during treatment with aminoglutethimide in breast cancer patients. Preliminary findings Clin Pharmacokinet 13 1987 393 406
35. P.E. Lønning, P. Bakke, T. Thorsen, B. Olsen, and A. Gulsvik Plasma levels of estradiol, estrone, estrone sulfate and sex hormone binding globulin in patients receiving rifampicin J Steroid Biochem 33 1989 631 635
36. J. Geisler, I.H. Omsjø, S.I. Helle, D. Ekse, T. Silsand, and P.E. Lønning Plasma oestrogen fractions in postmenopausal women receiving hormone replacement therapy: influence of route of administration and cigarette smoking J Endocrinol 162 1999 265 270
37. C. Longcope, and S. Baker Androgen and estrogen dynamics: relationship with age, weight, and menopausal status J Clin Endocrinol Metab 76 1993 601 604
38. P.E. Lønning, D.C. Johannessen, and T. Thorsen Alterations in the production rate and the metabolism of oestrone and oestrone sulphate in breast cancer patients treated with aminoglutethimide Br J Cancer 60 1989 107 111
39. J.M. Dixon, L. Renshaw, O. Young, J. Murray, E.J. Macaskill, and M. McHugh et al. Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer J Clin Oncol 26 2008 1671 1676
40. I.E. Smith, M. Dowsett, Y.S. Yap, G. Walsh, P.E. Lønning, and R.J. Santen et al. Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: Caution and suggested guidelines J Clin Oncol 24 2006 2444 2447